News coverage about AngioDynamics (NASDAQ:ANGO) has trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AngioDynamics earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 46.7728294285809 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

AngioDynamics (NASDAQ:ANGO) traded up 0.55% during mid-day trading on Friday, reaching $16.36. 157,969 shares of the company’s stock traded hands. The company has a 50-day moving average of $16.21 and a 200-day moving average of $16.17. AngioDynamics has a 52-week low of $14.80 and a 52-week high of $18.18. The company has a market capitalization of $598.45 million, a price-to-earnings ratio of 119.42 and a beta of 1.15.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The business had revenue of $86.90 million during the quarter, compared to the consensus estimate of $90.72 million. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.19 EPS. Equities research analysts expect that AngioDynamics will post $0.67 EPS for the current year.

A number of research firms have recently issued reports on ANGO. BidaskClub downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Cantor Fitzgerald lifted their price objective on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Zacks Investment Research downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research report on Thursday, July 20th. Canaccord Genuity restated a “hold” rating and set a $17.00 price objective on shares of AngioDynamics in a research report on Tuesday, July 18th. Finally, Barclays PLC cut their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. AngioDynamics has an average rating of “Hold” and an average target price of $18.50.

ILLEGAL ACTIVITY NOTICE: “AngioDynamics (NASDAQ:ANGO) Earns Media Impact Score of 0.12” was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/13/angiodynamics-nasdaqango-earns-media-impact-score-of-0-12.html.

In related news, CEO James C. Clemmer acquired 20,000 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were purchased at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the purchase, the chief executive officer now owns 86,683 shares in the company, valued at $1,355,722.12. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Clemmer acquired 5,000 shares of the company’s stock in a transaction on Friday, July 21st. The stock was bought at an average price of $15.79 per share, for a total transaction of $78,950.00. Following the purchase, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 25,316 shares of company stock valued at $396,806. 1.88% of the stock is owned by insiders.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Insider Buying and Selling by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.